Pharmacological approaches to the treatment of tinnitus
Tinnitus is the conscious perception of a phantom sound in the absence of an external source. For 1 in 100 of the general population, the condition severely affects quality of life. In spite of the fact that the market for a drug indicated for tinnitus relief is huge, there are still no FDA-approved...
Guardado en:
Publicado: |
2010
|
---|---|
Materias: | |
Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13596446_v15_n7-8_p300_Elgoyhen http://hdl.handle.net/20.500.12110/paper_13596446_v15_n7-8_p300_Elgoyhen |
Aporte de: |
id |
paper:paper_13596446_v15_n7-8_p300_Elgoyhen |
---|---|
record_format |
dspace |
spelling |
paper:paper_13596446_v15_n7-8_p300_Elgoyhen2023-06-08T16:11:24Z Pharmacological approaches to the treatment of tinnitus acamprosate alprazolam amitriptyline atorvastatin benzodiazepine carbamazepine clonazepam cyclandelate diazepam duloxetine ebselen furosemide gabapentin Ginkgo biloba extract lamotrigine lidocaine memantine misoprostol neramexane nimodipine nortriptyline paroxetine placebo sertraline sulpiride tricyclic antidepressant agent trimipramine unindexed drug venlafaxine vestipitant clinical trial cognitive therapy disease severity drug industry ear disease feedback system head and neck injury human loudness recruitment noise patient counseling prevalence quality of life review risk factor stress tinnitus vestibulocochlear nerve disease visual analog scale Animals Drug Discovery Drug Industry Humans Tinnitus Tinnitus is the conscious perception of a phantom sound in the absence of an external source. For 1 in 100 of the general population, the condition severely affects quality of life. In spite of the fact that the market for a drug indicated for tinnitus relief is huge, there are still no FDA-approved drugs, and the quest for a tinnitus-targeted compound faces important challenges. A wide variety of drugs have been used off-label to treat tinnitus sufferers, with limited but significant effects in subsets of patients. If the compounds being developed at present by the pharmaceutical industry finally reach the market, they will establish a turning point in the treatment of this pathology. © 2009 Elsevier Ltd. 2010 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13596446_v15_n7-8_p300_Elgoyhen http://hdl.handle.net/20.500.12110/paper_13596446_v15_n7-8_p300_Elgoyhen |
institution |
Universidad de Buenos Aires |
institution_str |
I-28 |
repository_str |
R-134 |
collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
topic |
acamprosate alprazolam amitriptyline atorvastatin benzodiazepine carbamazepine clonazepam cyclandelate diazepam duloxetine ebselen furosemide gabapentin Ginkgo biloba extract lamotrigine lidocaine memantine misoprostol neramexane nimodipine nortriptyline paroxetine placebo sertraline sulpiride tricyclic antidepressant agent trimipramine unindexed drug venlafaxine vestipitant clinical trial cognitive therapy disease severity drug industry ear disease feedback system head and neck injury human loudness recruitment noise patient counseling prevalence quality of life review risk factor stress tinnitus vestibulocochlear nerve disease visual analog scale Animals Drug Discovery Drug Industry Humans Tinnitus |
spellingShingle |
acamprosate alprazolam amitriptyline atorvastatin benzodiazepine carbamazepine clonazepam cyclandelate diazepam duloxetine ebselen furosemide gabapentin Ginkgo biloba extract lamotrigine lidocaine memantine misoprostol neramexane nimodipine nortriptyline paroxetine placebo sertraline sulpiride tricyclic antidepressant agent trimipramine unindexed drug venlafaxine vestipitant clinical trial cognitive therapy disease severity drug industry ear disease feedback system head and neck injury human loudness recruitment noise patient counseling prevalence quality of life review risk factor stress tinnitus vestibulocochlear nerve disease visual analog scale Animals Drug Discovery Drug Industry Humans Tinnitus Pharmacological approaches to the treatment of tinnitus |
topic_facet |
acamprosate alprazolam amitriptyline atorvastatin benzodiazepine carbamazepine clonazepam cyclandelate diazepam duloxetine ebselen furosemide gabapentin Ginkgo biloba extract lamotrigine lidocaine memantine misoprostol neramexane nimodipine nortriptyline paroxetine placebo sertraline sulpiride tricyclic antidepressant agent trimipramine unindexed drug venlafaxine vestipitant clinical trial cognitive therapy disease severity drug industry ear disease feedback system head and neck injury human loudness recruitment noise patient counseling prevalence quality of life review risk factor stress tinnitus vestibulocochlear nerve disease visual analog scale Animals Drug Discovery Drug Industry Humans Tinnitus |
description |
Tinnitus is the conscious perception of a phantom sound in the absence of an external source. For 1 in 100 of the general population, the condition severely affects quality of life. In spite of the fact that the market for a drug indicated for tinnitus relief is huge, there are still no FDA-approved drugs, and the quest for a tinnitus-targeted compound faces important challenges. A wide variety of drugs have been used off-label to treat tinnitus sufferers, with limited but significant effects in subsets of patients. If the compounds being developed at present by the pharmaceutical industry finally reach the market, they will establish a turning point in the treatment of this pathology. © 2009 Elsevier Ltd. |
title |
Pharmacological approaches to the treatment of tinnitus |
title_short |
Pharmacological approaches to the treatment of tinnitus |
title_full |
Pharmacological approaches to the treatment of tinnitus |
title_fullStr |
Pharmacological approaches to the treatment of tinnitus |
title_full_unstemmed |
Pharmacological approaches to the treatment of tinnitus |
title_sort |
pharmacological approaches to the treatment of tinnitus |
publishDate |
2010 |
url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13596446_v15_n7-8_p300_Elgoyhen http://hdl.handle.net/20.500.12110/paper_13596446_v15_n7-8_p300_Elgoyhen |
_version_ |
1768545845804793856 |